Código QR

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate. Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 1...

Descrición completa

Gardado en:
Principais autores: Florian Ottenlinger, Christoph Alexander Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin Schmidt, Hanns Ackermann, Josef Pfeilschifter, Heinfried H. Radeke
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2016-11-01
Series:Frontiers in Pharmacology
Assuntos:
Ceramides
Interferon-beta
Multiple Sclerosis
Sphingolipids
fingolimod
natalizumab
Acceso en liña:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00412/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares